Fundamental Analysis of ONCOLOGY INSTITUTE INC/THE(NASDAQ:TOI) stock

Fundamental Rating

Taking everything into account, TOI scores 3 out of 10 in our fundamental rating. TOI was compared to 117 industry peers in the Health Care Providers & Services industry. TOI may be in some trouble as it scores bad on both profitability and health. TOI is valued quite expensive, but it does show an excellent growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

TOI had negative earnings in the past year.

In the past year TOI has reported a negative cash flow from operations.

TOI had negative earnings in 4 of the past 5 years.

The reported operating cash flow has been mixed in the past 5 years: TOI reported negative operating cash flow in multiple years.

1.2 Ratios

TOI has a Return On Assets of -32.44%. This is amonst the worse of the industry: TOI underperforms 81.03% of its industry peers.

TOI has a worse Return On Equity (-119.03%) than 76.72% of its industry peers.

		Industry Rank	Sector Rank
ROA	-32.44%
ROE	-119.03%
ROIC	N/A

ROA(3y)-12.59%

ROA(5y)-13.25%

ROE(3y)-43.14%

ROE(5y)-37.96%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

TOI has a worse Gross Margin (18.38%) than 64.66% of its industry peers.

TOI's Gross Margin has declined in the last couple of years.

The Profit Margin and Operating Margin are not available for TOI so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	18.38%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-2.26%

GM growth 5Y-4.59%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

TOI does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, TOI has more shares outstanding

TOI has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of 0.59, we must say that TOI is in the distress zone and has some risk of bankruptcy.

TOI has a Altman-Z score of 0.59. This is in the lower half of the industry: TOI underperforms 61.21% of its industry peers.

A Debt/Equity ratio of 1.52 is on the high side and indicates that TOI has dependencies on debt financing.

The Debt to Equity ratio of TOI (1.52) is worse than 66.38% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	1.52
Debt/FCF	N/A
Altman-Z	0.59

ROIC/WACCN/A

WACC7.19%

2.3 Liquidity

A Current Ratio of 4.12 indicates that TOI has no problem at all paying its short term obligations.

The Current ratio of TOI (4.12) is better than 91.38% of its industry peers.

TOI has a Quick Ratio of 3.73. This indicates that TOI is financially healthy and has no problem in meeting its short term obligations.

Looking at the Quick ratio, with a value of 3.73, TOI belongs to the top of the industry, outperforming 91.38% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	4.12
Quick Ratio	3.73

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

TOI shows a strong growth in Revenue. In the last year, the Revenue has grown by 28.42%.

TOI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 23.43% yearly.

EPS 1Y (TTM)N/A

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q16%

Revenue 1Y (TTM)28.42%

Revenue growth 3Y20.03%

Revenue growth 5Y23.43%

Revenue growth Q2Q20.12%

3.2 Future

Based on estimates for the next years, TOI will show a very strong growth in Earnings Per Share. The EPS will grow by 32.33% on average per year.

The Revenue is expected to grow by 22.73% on average over the next years. This is a very strong growth

EPS Next Y47.3%

EPS Next 2Y32.33%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year28.7%

Revenue Next 2Y22.73%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TOI. In the last year negative earnings were reported.

Also next year TOI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as TOI's earnings are expected to grow with 32.33% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y32.33%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

TOI does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ONCOLOGY INSTITUTE INC/THE

NASDAQ:TOI (5/3/2024, 7:22:21 PM)

After market: 1.11 +0.04 (+3.74%)

1.07

-0.09 (-7.76%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Providers & Services

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap79.51M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-32.44%
ROE	-119.03%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	18.38%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover1.55

Health

		Industry Rank	Sector Rank
Debt/Equity	1.52
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	4.12
Quick Ratio	3.73
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)N/A

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y47.3%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)28.42%

Revenue growth 3Y20.03%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

Scheduled Maintenance

ONCOLOGY INSTITUTE INC/THE (TOI)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens